Follow us on Twitter
This page is updated frequently with new Acellular-related patent applications. Subscribe to the Acellular RSS feed to automatically get the update: related Acellular RSS feeds. RSS updates for this page: Acellular RSS
|| List of recent Acellular-related patents
| Fluorescent potassium ion sensors|
This disclosure relates generally to potassium ion sensors and monomers derived from such sensors. The disclosure also provides for polymers (e.g., random copolymers, nanoparticles, polymer thin films, and sensors) having polymerized monomeric potassium ion sensors as described herein.
| Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases|
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..
| Protein involved in detection of cancer metastasis and a treatment thereof|
Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is trpv4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues.
| Methods for treating and preventing neutrophil-derived net toxicity and thrombosis|
Embodiments of the technology described herein are based upon the discoveries that neturophil extracellular traps (nets) provide a stimulus for thrombus formation and that nets are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of nets and thrombosis caused by nets.
| Ddr1-binding agents and methods of use thereof|
The present invention relates to ddr1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of ddr1 and modulate ddr1 activity.
| Protein comprising truncated form of extracellular region protein of frizzled2, and pharmaceutical composition for treating bone diseases which comprises said protein|
The present invention provides a protein comprising a truncated form of an extracellular region protein of frizzled 2, which has higher secretion activity than that of a known protein comprising an extralellular cysteine-rich domain of frizzled 2 in a production cell and bone mass-increasing activity higher than or equal to that of the known protein, or dna encoding said protein.. .
| Use of matrix metalloproteinase inhibitors to treat tuberculosis|
The present invention provides a method for treating a subject suffering from tuberculosis which comprises administering to the subject a composition comprising an amount of an inhibitor of a matrix metalloproteinase (mmp) in an amount effective to treat the subject, such that the therapeutic effect of said composition is different than the therapeutic effect attributable to the antibiotic properties of said composition. The present invention also provides a method for reducing or inhibiting destruction of lung extracellular matrix in a subject comprising administering to the subject at risk for such destruction a composition comprising an amount of an inhibitor of a matrix metalloproteinase (mmp) in an amount effective to reduce or inhibit destruction of lung extracellular matrix in the subject..
|Modified chimeric polypeptides with improved pharmacokinetic properties|
The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
|Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer|
The present invention provides compositions and methods for detection and analysis of intracellular binding of a bioactive agent to a cellular target. In particular, provided herein are bioactive agents tethered to fluorophores, cellular targets fused to bioluminescent reporters, and methods of detecting and analyzing the interaction of bioactive agents with cellular targets therewith..
|Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer|
The present invention provides compositions and methods for detection and analysis of intracellular binding of a bioactive agent to a cellular target. In particular, provided herein are bioactive agents tethered to fluorophores, cellular targets fused to bioluminescent reporters, or portions, components, or subunits of bioluminescent reporters, and methods of detecting and analyzing the interaction of bioactive agents with cellular targets therewith..
The present disclosure relates to hydrolysis of hexose-δ-lactones by use of an s. Thermophile extracellular aldonolactonase.
|Extracellular polyhydroxyalkanoates produced by genetically engineered microorganisms|
The present invention is in the field of biosynthesis of polyhydroxyalkanoates (pha). The invention relates to a genetically engineered microorganism having at least one gene involved in the metabolism, preferably in the production, of polyhydroxyalkanoates (pha).
|Non-invasive detection of fetal genetic traits|
Blood plasma of pregnant women contains fetal and (generally>90%) maternal circulatory extracellular dna. Most of said fetal dna contains 500 base pairs, said maternal dna having a greater size.
|Topical anti-inflammatory compositions and uses thereof|
Disclosed are pharmaceutical compositions and topical formulations thereof that include multiple, phytochemically-active, nutraceutical compounds, and that possess potent anti-inflammatory and extracellular matrix-stabilizing properties both in vitro and in vivo. Also disclosed are prophylactic and therapeutic methods, as well as dosing regimens and medicaments for use in preventing chronic disease, for treating acute or long-term inflammatory-mediated conditions in affected or at-risk subjects, and for stabilizing one or more components of the mammalian extracellular matrix..
|Extracellular targeted drug conjugates|
Extracellular-targeted drug conjugates (edc) in which a targeting moiety targeting a protein associated with the na,k-atpase is linked to a drug that interacts with the na,k-atpase through a linker a stable linker are useful in the treatment of disease and as tools for the evaluation of biological systems.. .
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
|Method for treating oncological diseases|
A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular dna into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a dnase enzyme and, more particularly, as a dnase i enzyme.
|Measurement of body fluid volumes|
The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ecfv), total vascular plasma volume (tvpv) and interstitial fluid volume (ifv).
|Method for recycling metals|
A method for recycling metals is provided by using extracellular proteins excreted by a specific thermophilic bacteria strain, tepidimonas fonticaldi sp. Nov., in which the extracellular proteins show excellent metal-ion binding ability, being useful in recycling rare earth metal ions and precious metal ions from geothermal fluids, boiler solutions, industrial wastewater or hard water..
|Systems and methods for sterilization|
Systems for sterilization of tissues, including acellular tissue matrices, comprising a package having a portion permeable to supercritical carbon dioxide and a portion impermeable to moisture are described. Methods of sterilizing acellular tissue matrices from soft tissues or demineralized bone are provided..
|Galactose-rich polysaccharide, process for the production of the polymer and its applications|
This invention concerns a biopolymer consisting of a polysaccharide composed of galactose (50-90%), glucose (1-25%), mannose (1-25%) and rhamnose (0.5-20%), which may additionally contain, in trace amounts, xylose, fucose, ribose, arabinose and/or fructose. The galactose-rich polymer also contains non-saccharide components, namely, acyl groups.
|Extracellular matrix material conduits and methods of making and using same|
Extracellular matrix (ecm) valve conduits are disclosed. Methods for regenerating atrioventricular valves to replace defective atrioventricular valves within a heart of a subject using the ecm valve conduits are also disclosed.
|Production of fungal extracellular immune stimulating compounds|
A process is described for the production of an immunostimulant by submerged cultivation of ganoderma lucidum in which mycelium from agar plates or a fermentation broth is added to a liquid medium in a shake flask or a bioreactor containing nutrients such as malt extract, yeast extract, peptone and glucose having access to air or to which air is added, and which is kept in constant movement at approx. 28° c.
|Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto|
Methods, assays, and apparatus are disclosed for testing of antigens associated with intestinal and/or blood-brain barrier permeability. For example, blood, saliva or other bodily fluid can be tested for binding (1) to a bacterial toxin (preferably a lipopolysaccharide), and (2) binding to tissue antigens selected from at least one of (a) a gut-related antigen and (b) a blood brain barrier-related antigen.
|Biomarkers for myocardial ischemia|
This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) lumican and/or (ii) extracellular matrix protein 1 and/or (iii) carboxypeptidase n; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention..
|Strain of cobetia marina and biosurfactant extract obtained from same|
The invention discloses a bacterial strain of non pathogenic cobetia marina useful in aquaculture, corresponding to an isolated cobetia marina strain, gram negative, oxidase positive, deposited under registry number cect n° 7764; grows with dibenzothiophene (dbt) as the only carbon source. Also disclosed is a method to obtain a biosurfactant surfactant extract comprising growing strain cobetia marina (mm1ida2h-1) cect n° 7764 in a reactor with liquid growth medium from 24 to 48 hours at a temperature between 10 and 35° c., ph 6 to 8; constant stirring between 100 to 400 rpm and oxygen saturation between 10 to 21%; until obtaining a grown cell culture and extracellular products plus inorganic salts; separating the cells, lyophilizing supernatant, sieve the obtained powder and dry.
|Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma|
The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (nt-3 or nt3), to the extracellular domain or trkc receptor and/or to inhibit the dimerization of the intracellular domain of the trkc receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3.
|Human cdr-grafted antibody and antibody fragment thereof|
A human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human cc chemokine receptor 4 (ccr4) but does not react with a human blood platelet; a human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of ccr4 and has a cytotoxic activity against a ccr4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.. .
|Compositions and methods for diagnosing and treating cancer|
An isolated antibody that specifically binds to an extracellular domain of human ddr2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount..
|Neuroprotective polyphenol analogs|
The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration.
|Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells|
Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous notch intracellular domain. The transplanted cells form a pathway along which endogenous neurogenic cells proliferate and migrate from the subventricular zone to the site of injury..
|Method of ex vivo cellular growth|
The present invention relates generally to an ex vivo method of producing a population of cells and materials for use therewith. More particularly, the present invention is directed to an ex vivo method of generating the growth of a population of blood-derived cells and materials for use therewith.
|Compositions for regenerating defective or absent myocardium|
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function..
|Immunoglobulin-bound extracellular vesicles and uses thereof|
Provided are methods of isolating igg-bound (e.g., igg-bound or protein g-recognized igg-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the igg (e.g., igg2 or protein g-recognized igg) is bound to an antigen present on the surface of the extracellular vesicle and the igg (e.g., igg2 or protein g-recognized igg) is an endogenous antibody. Also provided are methods of diagnosing a cancer in a subject that include detecting the presence of one or more tumor antigens in an isolated igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle, and methods of treating a subject that include administering one or more cancer therapeutics to a subject having an igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle that contains one or more tumor antigens..
|Extracellular vesicle-associated protein markers of cancer|
Extracellular vesicle-associated protein biomarkers for use in diagnosing and staging carcinomas, e.g., lung and ovarian cancers.. .
|Mesh enclosed tissue constructs|
Described is a heart valve leaflet manufactured from a mesh material. The mesh material may have an ability to capture circulatory/stationary/migratory cells of the body to become biologically active.
Popular terms: [SEARCH]
Acellular topics: Extracellular, Intracellular, Recurrence, Antagonist, Stem Cells, Immunoglobulin, Adhesion Molecule, Metastasis, Cancer Cells, Cancer Cell, Proliferative Disorder, Metalloprotein, Proliferative, Fibroblast, Polypeptide
Follow us on Twitter
This listing is a sample listing of patent applications related to Acellular for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Acellular with additional patents listed. Browse our RSS directory or Search for other possible listings.